Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability

Anil Thankappan(United States Military Academy), Patrick André(Institut des Vaisseaux et du Sang), Karen Leander(United States Military Academy), John M. Levorse(Howard Hughes Medical Institute), Dietmar Seiffert(Bristol-Myers Squibb (United States)), Joseph M. Metzger(University of Minnesota Medical Center), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Nina Jochnowitz(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marija Tadin‐Strapps, Ross Bentley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Walter Strapps, Myung K. Shin(International Genetically Engineered Machine Foundation), Lizbeth Hoos(AIL Research (United States)), Zhu Chen(University of Science and Technology of China), Weizhen Wu(Third Affiliated Hospital of Guangzhou Medical University), Zuo‐Feng Zhang(University of California, Los Angeles), Yuchen Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yiming Xu(Tsinghua University), Kunal Desai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tian‐Quan Cai(Merck & Co., Inc., Rahway, NJ, USA (United States)), KehDih Lai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marti DiPietro(United States Military Academy)
Thrombosis and Haemostasis
March 19, 2015
Cited by 7


Related Papers